The business objective of Ncardia lies in the area of pre-clinical biotechnology, specifically in the development and production of stem cell-derived cell types (e.g. cardiac & neuronal cells) and cell-based assays that enable drug development. These innovative and proprietary cell types and assays accelerate and improve drug candidate selection, lower costs and thus increase overall drug development efficiency.